HAS Healthcare Advanced Synthesis SA Receives EcoVadis Gold Medal Certification for the Third Consecutive Year!

Biasca, Switzerland, July 1st 2024

HAS Healthcare Advanced Synthesis SA (HAS), an international leader in the development and manufacturing of Active Pharmaceutical Ingredients (APIs), Advanced Intermediates, Highly Potent APIs (HPAPIs) and anticancer compounds, is proud to announce that it has been awarded the EcoVadis Gold Medal certification for the third consecutive year, placing the company in the top 5% of the world's most sustainable businesses.

EcoVadis, a globally recognized provider of business sustainability ratings, awards the Gold Medal to companies that demonstrate outstanding performance across a range of sustainability criteria. This prestigious recognition highlights HAS Healthcare Advanced Synthesis's unwavering commitment to Corporate Social Responsibility (CSR) and sustainable business practices.

EcoVadis operates the first collaborative platform providing sustainability ratings and performance improvement tools for global supply chains. Their methodology covers 21 sustainability criteria across four themes: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. The EcoVadis assessment is built on international sustainability standards, including the Global Reporting Initiative (GRI), the United Nations Global Compact (UNGC), and ISO 26000.

At HAS Healthcare Advanced Synthesis, sustainability is more than just a buzzword it's a core value that drives every aspect of our operations. From the responsible use of resources to minimizing environmental impact, we are dedicated to making a positive difference in the communities we serve.

Dr. Waldo Mossi, PhD, CEO, HAS Healthcare Advanced Synthesis, commented:

"We are honored to receive the EcoVadis Gold Medal for the third year in a row, and this recognition serves as a testament to the hard work and commitment of our entire team."

About HAS Healthcare Advanced Synthesis: HAS Healthcare Advanced Synthesis is a trusted CDMO that offers comprehensive services, including the development and manufacturing of Active Pharmaceutical Ingredients (APIs), cGMP Advanced Intermediates, High Potency APIs (HPAPIs), and anticancer compounds.

The company exclusively caters to its clients' needs providing reliable and tailor-made solutions from clinical to commercial supply. Established in 1984, the production plant is located in Biasca, Switzerland. It undergoes regular inspections by regulatory agencies such as the FDA and SwissMedic. HAS operates dedicated manufacturing facilities with production capacities ranging from grams to tens of kilograms for HPAPIs and anticancer compounds, and from kilograms to tens of tons for APIs, adhering to cGMP standards.

For more information about HAS Healthcare Advanced Synthesis, please visit our Website and LinkedIn profile

Contact Press Office

HAS Healthcare Advanced Synthesis
Biasca, Switzerland
Giacomo Braglia
Tel: +41 (0) 91 873 94 00
Email: [email protected]